The company is now down by 7.41% at $3.61 and is one of the laggers in today’s market. 68 shares have been traded.
Investors are a little more bullish lately if you take note of the downtick in short interest. The firm saw a fall in short interest from September 29, 2017 to October 13, 2017 of -4.62%. Short interest fell 10,593 over that period. The short-interest ratio decreased to 1.0 and the percentage of shorted shares was 0.02% on October 13.
Here are a few substantial investment firms who have updated their positions. Royal Bank Of Canada cut its holdings by selling 1 shares a decrease of 50.0% in the quarter. Royal Bank Of Canada now controls 1 shares valued at $0. The value of the position overall is down by nan%. Bank Of America Corp /de/ grew its position by buying 108 shares an increase of 372.4%. Bank Of America Corp /de/ claims 137 shares with a value of $0. The total value of its holdings decreased nan%.
As of quarter end Deutsche Bank Ag had sold a total of 300 shares trimming its stake by 97.4%. The value of the investment in Cesca Therapeutics I went from $0 to $0 a change of $0 for the reporting period. Citadel Advisors LLC divested its stake by shedding 7,545 shares a decrease of 42.2% from 06/30/2017 to 09/30/2017. Citadel Advisors LLC now holds 10,346 shares worth $37,000. The total value of its holdings decreased 33.9%.
The company currently has a P/E ratio of N/A and market capitalization is 35.99M. As of the latest earnings report the EPS was $-0.91 with 9.97M shares now outstanding.
Cesca Therapeutics Inc., launched on July 3, 1986, is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is involved in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry..